The Outcome of Prompt Concomitant Single-Dose High-Concentration Intratympanic and Tapered Low-Dose Oral Systemic Corticosteroid Treatment for Sudden Deafness

J Int Adv Otol. 2020 Aug;16(2):201-206. doi: 10.5152/iao.2020.8341.

Abstract

Objectives: To investigate the efficacy of prompt concomitant corticosteroid treatment with single application of high-concentration intratympanic (IT) dexamethasone and tapered low-dose systemic methylprednisolone of an idiopathic sudden sensorineural hearing loss (ISSNHL).

Materials and methods: Between September 2017 and September 2019, 86 adult patients met the criteria for the diagnosis of ISSNHL at baseline evaluation. The patients received immediate concomitant treatment with single high-concentration (24 mg/mL) IT dexamethasone and low-dose (48 mg) oral methylprednisolone for 1 week followed by tapered doses. Improvement in pure-tone average (PTA) and word recognition score (WRS) was determined after 1 and 6 months.

Results: A total of 63 patients met the requirements for the analysis. PTA improved in 71% and WRS improved in 59% of patients with ISSNHL. PTA and WRS were statistically significantly different at different time points during the intervention (p<0.0005). Hearing improved in all measured frequencies from 125 to 8000 Hz until the second follow-up. In 65.4% of patients with tinnitus, the WRS has improved compared with 27.3% without tinnitus (p<0.05). In 69.2% of patients without vertigo, the WRS has improved compared with 41.7% with vertigo (p<0.05).

Conclusion: Prompt concomitant single high-concentration IT and low-dose systemic corticosteroid treatment is efficient in recovering hearing loss and speech discrimination in ISSNHL. Tinnitus positively predicts hearing outcome. Vertigo negatively predicts speech discrimination recovery.

MeSH terms

  • Audiometry, Pure-Tone
  • Dexamethasone / administration & dosage*
  • Drug Therapy, Combination
  • Female
  • Glucocorticoids / administration & dosage*
  • Hearing / drug effects*
  • Hearing Loss, Sudden / drug therapy*
  • Humans
  • Injection, Intratympanic
  • Male
  • Methylprednisolone / administration & dosage*
  • Middle Aged
  • Prospective Studies
  • Speech Perception
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Dexamethasone
  • Methylprednisolone